Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q2 2022 · 10-Q
Revenue$536.00K$536.00K−75.8% vs Q2 2021 Net Income-$31.16M-$31.16MN/M vs Q2 2021 EPS Diluted-$0.55-$0.55N/M vs Q2 2021 Operating Income-$30,315,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$17,412,000N/M Margins · derivedOperating margin-5655.8%−4641.4 pt vs Q2 2021
Net margin-5813.1%−4816.3 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 9, 2022 · 40 d after period end